LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Regeneron Pharmaceuticals Inc

Closed

SectorHealthcare

594.37 1.83

Overview

Share price change

24h

Current

Min

577.46

Max

594.92

Key metrics

By Trading Economics

Income

-109M

809M

Sales

-761M

3B

P/E

Sector Avg

14.64

56.602

EPS

8.22

Dividend yield

0.67

Profit margin

26.701

Employees

15,158

EBITDA

-54M

1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+40.88% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.67%

2.45%

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-13B

62B

Previous open

592.54

Previous close

594.37

News Sentiment

By Acuity

36%

64%

122 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2025, 11:07 UTC

Earnings

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4 lut 2025, 12:13 UTC

Earnings

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

29 kwi 2025, 18:04 UTC

Market Talk
Earnings

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 kwi 2025, 14:39 UTC

Market Talk
Earnings

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 kwi 2025, 14:29 UTC

Earnings

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 kwi 2025, 13:11 UTC

Earnings

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 kwi 2025, 10:32 UTC

Earnings

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 kwi 2025, 10:30 UTC

Earnings

Regeneron Pharma 1Q Rev $3.03B >REGN

29 kwi 2025, 10:30 UTC

Earnings

Regeneron Pharma 1Q Net $808.7M >REGN

29 kwi 2025, 10:30 UTC

Earnings

Regeneron Pharma 1Q EPS $7.27 >REGN

29 kwi 2025, 10:30 UTC

Earnings

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 kwi 2025, 10:51 UTC

Top News

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 lut 2025, 11:58 UTC

Earnings

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 lut 2025, 11:37 UTC

Earnings

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 lut 2025, 11:37 UTC

Earnings

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 lut 2025, 11:36 UTC

Earnings

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 lut 2025, 11:35 UTC

Earnings

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 lut 2025, 11:35 UTC

Earnings

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 lut 2025, 11:34 UTC

Earnings

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 lut 2025, 11:34 UTC

Earnings

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 lut 2025, 11:32 UTC

Earnings

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 lut 2025, 11:31 UTC

Earnings

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 sty 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 sty 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 paź 2024, 13:58 UTC

Earnings

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 paź 2024, 10:52 UTC

Earnings

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 paź 2024, 10:34 UTC

Earnings

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 paź 2024, 10:33 UTC

Earnings

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 paź 2024, 10:33 UTC

Earnings

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

40.88% upside

12 Months Forecast

Average 804.95 USD  40.88%

High 979 USD

Low 535 USD

Based on 21 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

18

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

542.44 / 599.76Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

122 / 382 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.